STADA and Calliditas announce the filing for full marketing authorization of Kinpeygo® in the EU
· Request submitted by STADA to EMA to convert conditional marketing authorization to standard marketing authorization for Kinpeygo treatment for primary IgA nephropathy · Submission to the CHMP for full approval is based on the full two-year data set from the Phase 3 NefIgArd clinical trial, as recently published in leading medical journal The Lancet · Kinpeygo is the first and only approved treatment in Europe for IgAN, a rare, progressive autoimmune disease of the kidney with a high unmet need. Bad Vilbel, Germany/Stockholm, Sweden – 28 September 2023 – Partners STADA and